ccm-3 Antibody

What is CCM-3 and why are antibodies against it important in research?

CCM-3, also known as Programmed Cell Death 10 (PDCD10), is a critical protein involved in maintaining blood-brain barrier integrity and vascular maturation. CCM-3 is one of three genes (alongside CCM1/KRIT1 and CCM2/MGC4607) associated with cerebral cavernous malformations (CCMs), which are vascular lesions characterized by enlarged and irregular blood vessels in the brain that increase risk of stroke, focal neurological defects, and seizures .

CCM-3 antibodies are crucial research tools because mutations in CCM3 result in a more severe form of the disease compared to mutations in other CCM genes, suggesting unique biological functions in the vasculature . These antibodies enable researchers to study CCM-3 protein expression, localization, interactions with other proteins, and functional roles in normal and pathological conditions. They are essential for elucidating the molecular mechanisms underlying CCM pathogenesis and identifying potential therapeutic targets.

What are the primary research applications for CCM-3 antibodies?

CCM-3 antibodies are utilized across multiple research applications:

• Protein detection and quantification: Western blotting to assess CCM-3 protein levels in different tissues or under various experimental conditions

• Protein localization: Immunofluorescence to visualize CCM-3 distribution within cells, particularly in relation to cellular structures like the Golgi apparatus

• Protein-protein interaction studies: Immunoprecipitation to investigate CCM-3's associations with binding partners such as GCKIII kinases and components of the STRIPAK complex

• Functional studies: Using antibodies to validate CCM-3 knockdown or knockout models generated through siRNA or CRISPR/Cas9 approaches

• Histopathological analysis: Examination of CCM-3 expression patterns in patient tissue samples and animal models of cerebral cavernous malformations

What are the optimal protocols for validating CCM-3 antibody specificity?

Rigorous validation of CCM-3 antibodies is essential for generating reliable experimental data. A comprehensive validation approach should include:

• Positive and negative control samples:

  • Positive controls: Wild-type cells/tissues known to express CCM-3

  • Negative controls: CCM-3 knockout or knockdown models

• Antibody titration: Determining optimal antibody concentrations to maximize specific signal while minimizing background. For western blotting, researchers typically use rabbit polyclonal CCM-3 antibodies (such as those from Proteintech Group) at dilutions between 1:500 and 1:2000 .

• Peptide competition assay: Pre-incubating the antibody with purified CCM-3 protein or immunizing peptide to confirm binding specificity.

• Multi-technique validation: Confirming CCM-3 detection across different methodologies (western blot, immunofluorescence, immunoprecipitation).

• Cross-reactivity assessment: Testing the antibody against related proteins to ensure specificity.

The most definitive validation involves comparing antibody staining patterns between wild-type and CCM-3-deficient samples generated through CRISPR/Cas9-mediated genome editing, which has been successfully employed to create CCM-3 knockout endothelial cell models .

What are the recommended immunofluorescence protocols for visualizing CCM-3 in endothelial cells?

For optimal CCM-3 visualization in endothelial cells, the following immunofluorescence protocol is recommended based on published research:

• Cell preparation:

  • Culture cells on μ-slides VI 0.4 (Ibidi) or similar substrates

  • Fix with 4% paraformaldehyde for 20 minutes at room temperature

  • Permeabilize with 0.1% Triton X-100 for 15 minutes

  • Block with 2% normal goat serum for 1 hour at room temperature

• Antibody incubation:

  • Primary antibody: Rabbit polyclonal anti-CCM-3 (typically 1:50-1:200 dilution)

  • Incubate for 1 hour at room temperature or overnight at 4°C

  • Secondary antibody: Anti-rabbit IgG conjugated with fluorophore (e.g., Alexa Fluor 555, 1:600 dilution)

  • Incubate for 1 hour at room temperature

• Co-staining options:

  • Endothelial markers: CD31 (1:50, mouse anti-CD31)

  • Smooth muscle markers: SM22α (1:350, rabbit anti-SM22α)

  • Nuclear staining: DAPI

  • Actin visualization: Phalloidin

• Imaging considerations:

  • Use confocal microscopy for optimal resolution

  • Include z-stack imaging to capture the full cellular distribution of CCM-3

  • Compare wild-type and CCM-3-deficient cells to confirm specificity of staining

This approach allows for detailed visualization of CCM-3 localization relative to cellular structures and assessment of cytoskeletal changes associated with CCM-3 deficiency.

How can CCM-3 antibodies help elucidate the protein's role in cell mechanics and cytoskeletal organization?

CCM-3 antibodies have been instrumental in revealing the protein's critical role in regulating cell mechanics and cytoskeletal organization:

• Cytoskeletal changes: Immunofluorescence studies using CCM-3 antibodies alongside F-actin staining (phalloidin) have demonstrated that CCM-3 deficiency leads to profound reorganization of the actin cytoskeleton. While wild-type endothelial cells show cortical actin localization, CCM-3-deficient cells develop increased stress fiber formation .

• Cell morphology assessment: CCM-3 antibodies help verify knockout/knockdown status when examining morphological changes. CCM-3-deficient endothelial cells display a more compact and rounded morphology compared to the typical elongated shape of wild-type cells .

• Mechanical property investigation: When combined with techniques like real-time deformability cytometry (RT-DC), CCM-3 antibodies help confirm that observed changes in cellular stiffness and elastic modulus are directly attributable to CCM-3 loss .

• Molecular pathway analysis: CCM-3 antibodies facilitate investigation of the signaling pathways through which CCM-3 regulates cytoskeletal dynamics, enabling researchers to distinguish between acute responses (cytoskeletal reorganization) and long-term effects (cell shape changes) .

These findings demonstrate that CCM-3 antibodies are essential tools for investigating the molecular mechanisms by which CCM-3 regulates endothelial cell mechanics, which is critical for understanding CCM pathogenesis.

What insights have CCM-3 antibodies provided about protein-protein interactions in the STRIPAK complex?

CCM-3 antibodies have been crucial in elucidating the role of CCM-3 within the Striatin-interacting phosphatase and kinase (STRIPAK) complex, revealing several key insights:

• Identification of binding partners: Immunoprecipitation with CCM-3 antibodies has helped identify that CCM-3 interacts with Germinal Center Kinase III (GCKIII) kinases as part of the STRIPAK complex, which includes phosphatase 2A and proteins involved in vesicular trafficking and cytoskeletal binding .

• Subcellular localization: CCM-3 antibodies have demonstrated that CCM-3 localizes with GCKIII kinases on the cis face of the Golgi apparatus, forming a complex with the Golgi matrix protein GM130, before relocating to the cytoplasmic STRIPAK complex .

• Functional relationships: Antibody-based studies have revealed that CCM-3 is critical for the translocation of GCKIII kinases from the cis-Golgi to the STRIPAK complex. CCM-3 silencing impairs the binding of GCKIII kinases to the STRIPAK complex while enhancing their binding to GM130 .

• Regulatory mechanisms: Immunofluorescence studies combined with CCM-3 antibodies have shown that CCM-3 regulates exocytosis in endothelial cells by interacting with UNC13B and STK24, inhibiting UNC13-mediated exocytosis of intracellular molecules like ANGPT-2 .

These findings highlight how CCM-3 antibodies have advanced our understanding of CCM-3's molecular interactions and cellular functions, particularly in regulating exocytosis and endothelial cell behavior through the STRIPAK complex.

How have CCM-3 antibodies contributed to understanding apoptosis regulation in CCM pathophysiology?

CCM-3 antibodies have provided crucial insights into the complex relationship between CCM-3 and apoptosis regulation:

These findings highlight the paradoxical nature of CCM-3 in cell death regulation – while named for a role in programmed cell death, its absence can promote endothelial cell survival under certain conditions, potentially contributing to the abnormal vascular proliferation characteristic of CCM lesions.

What are the common challenges when using CCM-3 antibodies and how can they be addressed?

Researchers frequently encounter several challenges when working with CCM-3 antibodies that can impact experimental outcomes:

• Specificity concerns:

  • Challenge: Cross-reactivity with related proteins or non-specific binding.

  • Solution: Validate antibody specificity using CCM-3 knockout/knockdown samples as negative controls. CRISPR/Cas9-based CCM-3 knockout models provide definitive validation tools .

• Low signal strength:

  • Challenge: Weak detection of endogenous CCM-3.

  • Solution: Optimize antibody concentration through titration experiments. Consider signal amplification systems or more sensitive detection methods. For western blotting, extending exposure times may help detect low abundance CCM-3.

• Background issues in immunofluorescence:

  • Challenge: High background obscuring specific CCM-3 signal.

  • Solution: Increase blocking time/concentration (e.g., using 2% normal goat serum for at least 1 hour), optimize antibody dilutions, and include additional washing steps .

• Antibody batch variation:

  • Challenge: Performance differences between antibody lots.

  • Solution: Test each new antibody lot against a standard sample. Consider creating a reference lysate or fixed cell preparation to compare antibody performance across experiments.

• Co-staining compatibility:

  • Challenge: Difficulty detecting CCM-3 alongside other markers due to species cross-reactivity.

  • Solution: Carefully plan antibody combinations to avoid species overlap or use directly conjugated primary antibodies. Sequential staining protocols may be necessary for complex co-localization studies.

How should researchers interpret discrepancies in results when using different CCM-3 antibodies?

When facing discrepancies between experiments using different CCM-3 antibodies, researchers should consider several factors:

• Epitope differences:

  • Different antibodies recognize distinct regions of CCM-3, which may be differentially accessible depending on protein conformation, post-translational modifications, or protein-protein interactions.

  • Approach: Map the epitopes recognized by each antibody and consider how protein folding or interactions might affect epitope accessibility.

• Antibody class and format:

  • Polyclonal versus monoclonal antibodies may yield different results. Polyclonal antibodies (like rabbit polyclonal CCM-3 from Proteintech Group) recognize multiple epitopes, potentially increasing sensitivity but reducing specificity compared to monoclonals .

  • Approach: Use both types when possible, as complementary tools rather than competing alternatives.

• Fixation compatibility:

  • Some antibodies perform better with specific fixation methods (paraformaldehyde versus methanol, etc.).

  • Approach: Test multiple fixation protocols with each antibody to determine optimal conditions.

• Isoform specificity:

  • Different antibodies may preferentially detect specific CCM-3 isoforms or post-translationally modified forms.

  • Approach: Characterize which CCM-3 variants each antibody detects using recombinant proteins or cells expressing specific isoforms.

• Validation strategy:

  • Approach: When results conflict, perform validation experiments using multiple techniques:

    • Compare results from western blot, immunofluorescence, and immunoprecipitation

    • Conduct genetic validation using siRNA knockdown or CRISPR/Cas9 knockout models

    • Consider antibody neutralization/competition experiments

By systematically addressing these factors, researchers can determine whether discrepancies reflect technical limitations or biologically meaningful phenomena.

How can CCM-3 antibodies be employed to investigate endothelial-to-mesenchymal transition in CCM pathogenesis?

CCM-3 antibodies are valuable tools for studying endothelial-to-mesenchymal transition (EndMT), a process implicated in CCM pathogenesis:

• Co-immunostaining protocols:
  Researchers can implement a multi-marker approach using CCM-3 antibodies alongside:

  • Endothelial markers: CD31 (1:50 dilution, mouse anti-CD31)

  • Mesenchymal markers: SM22α (1:350 dilution, rabbit anti-SM22α)

  • Cytoskeletal markers: F-actin (phalloidin staining)

  This approach allows for assessment of phenotypic changes in endothelial cells experiencing CCM-3 loss.

• Time-course experiments:
  Using CCM-3 antibodies at different time points after CCM-3 inactivation helps distinguish between acute and chronic effects on endothelial phenotype. Research indicates that while cytoskeletal reorganization and increased cell stiffness are immediate responses to CCM-3 loss, changes in cell morphology represent longer-term adaptations .

• Mechanistic pathway analysis:
  CCM-3 antibodies facilitate investigation of signaling pathways regulating EndMT:

  • Detection of transcription factors driving EndMT (e.g., Snail, Slug, Twist)

  • Analysis of TGF-β pathway activation status

  • Examination of GCKIII kinase localization and activity

• Quantitative assays:
  Combining CCM-3 antibodies with techniques like RT-DC provides quantitative metrics of EndMT progression:

  • Increased cell area

  • Enhanced elastic modulus/cell stiffness

  • Altered deformability profiles

These approaches enable researchers to mechanistically link CCM-3 dysfunction to endothelial cell phenotypic changes relevant to CCM pathogenesis.

What approaches can be used to study CCM-3's role in cell-extracellular matrix interactions?

CCM-3 antibodies are instrumental in elucidating how CCM-3 regulates interactions between cells and the extracellular matrix (ECM):

• ECM protein expression analysis:
  Researchers can use CCM-3 antibodies to validate CCM-3 knockout status when examining changes in ECM production. Studies have shown that CCM-3-deficient pericytes upregulate fibronectin and collagen IV production .

• Co-localization studies:
  Combining CCM-3 antibodies with staining for integrin receptors (particularly integrin-β1) helps visualize how CCM-3 influences adhesion molecule distribution and clustering.

• Cell adhesion strength assays:
  CCM-3 antibodies can confirm CCM-3 status in experiments measuring cell-ECM adhesion strength. Research indicates that CCM-3-deficient pericytes exhibit augmented adhesion to ECM proteins like fibronectin .

• Functional consequences assessment:
  Validated CCM-3 knockout models can be used to investigate how altered cell-ECM interactions affect:

  • Cell migration and spreading capabilities

  • Pericyte-endothelial cell association

  • Blood vessel structural integrity

• Mechanistic pathway investigation:
  CCM-3 antibodies help establish the molecular link between CCM-3 and ECM regulation through:

  • Signaling pathway analysis (especially integrin-linked kinase pathways)

  • Transcriptional regulation of ECM genes

  • Post-translational modifications affecting ECM protein secretion

This research direction is particularly important as it reveals how CCM-3 loss affects the brain microenvironment, potentially contributing to CCM lesion formation through altered cell-ECM interactions .

How should contradictory findings regarding CCM-3's role in apoptosis be reconciled?

The scientific literature contains seemingly contradictory findings regarding CCM-3's role in apoptosis, requiring careful interpretation:

• Context-dependent functions:

  • Original designation as PDCD10 (Programmed Cell Death 10) suggested a pro-apoptotic role

  • Some studies using CCM-3 antibodies showed that CCM-3 can prevent cytochrome c release after staurosporine treatment, indicating an anti-apoptotic function

  • Conversely, CCM-3-deficient endothelial cells show impaired activation of the caspase 3 apoptotic cascade, suggesting CCM-3 normally promotes certain apoptotic pathways

• Methodological considerations:

  • Different cell types: Effects may vary between endothelial cells, neurons, and other cell types

  • Acute versus chronic loss: Transient knockdown versus stable knockout models may yield different results

  • Stimulus-specific responses: CCM-3's role may differ depending on the apoptotic trigger (e.g., staurosporine versus oxidative stress)

• Recommended approach for reconciliation:

  • Clearly define experimental conditions, including cell type, CCM-3 manipulation method, and apoptotic stimulus

  • Use multiple, complementary apoptosis assays (e.g., caspase activation, TUNEL staining, annexin V binding)

  • Consider the temporal dimension: CCM-3 may have different effects at different stages of the apoptotic process

  • Examine pathway-specific effects rather than general "pro-" or "anti-apoptotic" classifications

• Implications for CCM pathogenesis:

  • The observed clonogenic survival advantage in CCM-3-deficient endothelial cells provides a mechanistic explanation for how these cells might contribute to CCM lesion formation

  • This suggests that targeting specific apoptotic pathways might offer therapeutic potential for CCM disease

What controls are essential when using CCM-3 antibodies for studying protein localization?

When investigating CCM-3 protein localization, researchers must implement rigorous controls to ensure valid and interpretable results:

• Antibody specificity controls:

  • Negative control: CCM-3 knockout or knockdown samples to confirm absence of signal

  • Peptide competition: Pre-incubation of antibody with purified CCM-3 protein should eliminate specific staining

  • Secondary-only control: Omitting primary antibody to assess background from secondary antibody

• Subcellular marker controls:

  • Co-staining with established subcellular compartment markers:

    • Golgi apparatus: GM130 (documented CCM-3 interaction partner)

    • Cytoskeleton: Phalloidin for F-actin visualization

    • Cell junctions: VE-cadherin for endothelial adherens junctions

    • Cell type markers: CD31 for endothelial cells, SM22α for smooth muscle cells

• Fixation and permeabilization controls:

  • Compare multiple fixation methods (e.g., 4% paraformaldehyde for 20 minutes)

  • Test different permeabilization approaches (e.g., 0.1% Triton X-100 for 15 minutes)

  • These can affect epitope accessibility and subcellular structure preservation

• Functional validation controls:

  • Confirm localization changes correlate with functional outcomes

  • For example, CCM-3 silencing impairs GCKIII kinase binding to the STRIPAK complex while enhancing binding to GM130, which should be detectable by localization changes

• Image acquisition controls:

  • Consistent exposure settings between samples

  • Z-stack imaging to fully capture three-dimensional protein distribution

  • Quantitative image analysis with objective parameters for co-localization assessment